Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

41.76
-0.4100-0.97%
Post-market: 41.760.00000.00%16:10 EDT
Volume:1.27M
Turnover:52.83M
Market Cap:6.65B
PE:-13.93
High:42.57
Open:42.15
Low:41.25
Close:42.17
Loading ...

William Blair Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
19 May

Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints

MT Newswires Live
·
19 May

Ionis Pharmaceuticals Announces Positive Essence Study Results

TIPRANKS
·
19 May

Ionis Pharmaceuticals Reports Positive Results from Essence Study of Olezarsen for Moderate Hypertriglyceridemia

Reuters
·
19 May

Ionis Announces Positive Topline Results From Essence Study of Olezarsen in People With Moderately Elevated Triglycerides

THOMSON REUTERS
·
19 May

Ionis Pharmaceuticals Inc - Phase 3 Core and Core2 Study Data Expected Q3 2025

THOMSON REUTERS
·
19 May

Ionis Pharmaceuticals Inc - Olezarsen Achieves All Key Secondary Endpoints

THOMSON REUTERS
·
19 May

Ionis Pharmaceuticals Inc - Olezarsen Shows Significant Triglyceride Reduction at 80 Mg and 50 Mg

THOMSON REUTERS
·
19 May

Ionis Pharmaceuticals Inc : Jefferies Raises Target Price to $83 From $77

THOMSON REUTERS
·
07 May

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

MT Newswires Live
·
02 May

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
01 May

Ionis Pharmaceuticals: Strong Buy Rating Backed by Robust Drug Performance and Strategic Market Expansion

TIPRANKS
·
01 May

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
01 May

Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges

TIPRANKS
·
01 May

Ionis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
01 May

Ionis Pharmaceuticals: Strong Financial Performance and Strategic Partnerships Justify Buy Rating Despite Adjusted Price Target

TIPRANKS
·
01 May

Ionis Pharmaceuticals: Strong Performance and Promising Pipeline Justify Buy Rating

TIPRANKS
·
01 May

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Benzinga
·
01 May

BUZZ-Ionis Pharma rises after lifting 2025 revenue forecast

Reuters
·
30 Apr

Ionis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
30 Apr